Neurotensins and their therapeutic potential : research field study
The natural tridecapeptide neurotensin has been emerged as a promising therapeutic scaffold for the treatment of neurological diseases and cancer. In this work, we aimed to identify the top 100 most cited original research papers as well as recent key studies related to neurotensins. The Web of Science Core Collection database was searched and the retrieved research articles were analyzed by using the VOSviewer software. The most cited original articles were published between 1973 and 2013. The top-cited article was by Carraway and Leeman reporting the discovery of neurotensin in 1973. The highly cited terms were associated with hypotension and angiotensin-converting-enzyme. The conducted analysis reveals the therapeutic potentials of neurotensin, and further impactful research toward its clinical development is warrantied.
| Errataetall: |
ErratumIn: Future Med Chem. 2021 Sep;13(17):1491. - PMID 34240613 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 12(2020), 19 vom: 02. Okt., Seite 1779-1803 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kan Yeung, Andy Wai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
39379-15-2 |
|---|
| Anmerkungen: |
Date Completed 14.07.2021 Date Revised 13.08.2021 published: Print-Electronic ErratumIn: Future Med Chem. 2021 Sep;13(17):1491. - PMID 34240613 Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2020-0124 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316024988 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316024988 | ||
| 003 | DE-627 | ||
| 005 | 20231225160201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2020-0124 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316024988 | ||
| 035 | |a (NLM)33032465 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kan Yeung, Andy Wai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurotensins and their therapeutic potential |b research field study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2021 | ||
| 500 | |a Date Revised 13.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Future Med Chem. 2021 Sep;13(17):1491. - PMID 34240613 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The natural tridecapeptide neurotensin has been emerged as a promising therapeutic scaffold for the treatment of neurological diseases and cancer. In this work, we aimed to identify the top 100 most cited original research papers as well as recent key studies related to neurotensins. The Web of Science Core Collection database was searched and the retrieved research articles were analyzed by using the VOSviewer software. The most cited original articles were published between 1973 and 2013. The top-cited article was by Carraway and Leeman reporting the discovery of neurotensin in 1973. The highly cited terms were associated with hypotension and angiotensin-converting-enzyme. The conducted analysis reveals the therapeutic potentials of neurotensin, and further impactful research toward its clinical development is warrantied | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Parkinson´s disease | |
| 650 | 4 | |a neurodegenerative diseases | |
| 650 | 4 | |a neurotensin | |
| 650 | 4 | |a peptidomimetics | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Central Nervous System Agents |2 NLM | |
| 650 | 7 | |a Neurotensin |2 NLM | |
| 650 | 7 | |a 39379-15-2 |2 NLM | |
| 700 | 1 | |a Georgieva, Maya G |e verfasserin |4 aut | |
| 700 | 1 | |a Kirilov, Kiril |e verfasserin |4 aut | |
| 700 | 1 | |a Balacheva, Aneliya A |e verfasserin |4 aut | |
| 700 | 1 | |a Peeva, Martina I |e verfasserin |4 aut | |
| 700 | 1 | |a Horbańczuk, Olaf K |e verfasserin |4 aut | |
| 700 | 1 | |a Horbańczuk, Jarosław O |e verfasserin |4 aut | |
| 700 | 1 | |a Lucarini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Durazzo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Souto, Eliana B |e verfasserin |4 aut | |
| 700 | 1 | |a Pajpanova, Tamara I |e verfasserin |4 aut | |
| 700 | 1 | |a Milella, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Atanasov, Atanas G |e verfasserin |4 aut | |
| 700 | 1 | |a Tzvetkov, Nikolay T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 12(2020), 19 vom: 02. Okt., Seite 1779-1803 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:19 |g day:02 |g month:10 |g pages:1779-1803 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2020-0124 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 19 |b 02 |c 10 |h 1779-1803 | ||